Química Farmacéutica
Permanent URI for this collection
Browse
Browsing Química Farmacéutica by Subject "Cáncer de mama"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
Item Seguimiento farmacoterapéutico bajo la metodología CTCAE en la evaluación de las reacciones adversas de la Doxorrubicina en pacientes con cáncer de mama polimedicadas(Universidad Santiago de Cali, 2024) Villanueva Gallego, Isabella; Ciro Monsalve, Yhors Alexander (Director); Echeverry Martínez, John JairoThe study deals in depth with adverse drug reactions (ADR) in breast cancer patients treated with Doxorubicin and other drugs simultaneously. It is highlighted that polymedication increases the risk of ADR, presenting interactions in 24% of the drugs administered, especially in the gastrointestinal, hematological and neurological systems. According to Naranjo's algorithm, it was observed that 64% of the ADRs have a possible relationship, 44% a probable relationship and 7% a doubtful relationship. Likewise, using the Common Terminology Criteria for Adverse Events (CTCAE), 85% of the reactions were classified as mild, 9% as moderate and 6% as severe. A remarkably high incidence of 98% was observed in patients with breast cancer, who were also under treatment with Doxorubicin and polymedication, presenting adverse reactions. This finding suggests a significant likelihood that ADRs are related to Doxorubicin administration in this specific population. The study highlights the importance of comprehensive evaluation and monitoring to prevent interactions and ADRs, proposing strategies such as pharmacotherapeutic follow-up, pharmacovigilance and education for medical staff and patients, in order to optimize safety and improve patients' quality of life